Eilean Therapeutics Advances Lomonitinib Clinical Trials with Single and Multiple Dose Studies

Eilean Therapeutics LLC, a company specializing in biopharmaceuticals, has successfully concluded a Phase 1 clinical trial for a drug named lomonitinib and is now starting a multiple ascending dose Phase 1 trial. Lomonitinib is a strong and precise inhibitor targeting FLT3/IRAK4 mutations, particularly those pertinent to hematologic and solid cancers. The initial Phase 1 study showed the drug is safe, with no significant side effects and effective target engagement at the dosages tested.

Iain Dukes, CEO of Eilean Therapeutics, remarked that completing the single ascending dose study is a key achievement, allowing for the accelerated development of lomonitinib. He noted that its safety profile could make it an effective treatment for AML with FLT3 mutations and potentially useful in other therapeutic areas influenced by IRAK4.

Lomonitinib works by inhibiting FLT3 ITD, TKD, and various other relevant FLT3 and IRAK4 mutations. These mutations are common in AML, with resistance typically arising from the FLT3-ITD-F691L gatekeeper mutation or IRAK4 escape pathways, both of which lomonitinib targets effectively.

Eilean Therapeutics is a biopharmaceutical firm co-founded by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd. The company aims to develop leading small molecule inhibitors that address mutations in hematologic and solid cancers, using a proprietary hybrid AI platform. This approach integrates proprietary data, chem/bio tools, and expertise from key partners to expedite the discovery and optimization of innovative therapies. The goal of Eilean Therapeutics is to create groundbreaking medicines that provide maximum clinical benefits for cancer treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!